Concepts (61)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Squamous Cell | 1 | 2022 | 19 | 0.760 |
Why?
|
| Polyps | 1 | 2022 | 26 | 0.740 |
Why?
|
| Vaginal Neoplasms | 1 | 2022 | 85 | 0.740 |
Why?
|
| Cost of Illness | 1 | 2021 | 164 | 0.630 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2021 | 98 | 0.620 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2022 | 197 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 314 | 0.530 |
Why?
|
| Quality of Life | 1 | 2021 | 1891 | 0.370 |
Why?
|
| Professional Practice | 1 | 2008 | 43 | 0.260 |
Why?
|
| Specialization | 1 | 2008 | 69 | 0.260 |
Why?
|
| Medicine | 1 | 2008 | 95 | 0.250 |
Why?
|
| Physician's Role | 1 | 2008 | 181 | 0.230 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 100 | 0.230 |
Why?
|
| Models, Theoretical | 1 | 2008 | 508 | 0.220 |
Why?
|
| Phage Therapy | 1 | 2024 | 7 | 0.210 |
Why?
|
| Carbapenems | 1 | 2024 | 12 | 0.210 |
Why?
|
| Klebsiella Infections | 1 | 2024 | 35 | 0.210 |
Why?
|
| Klebsiella pneumoniae | 1 | 2024 | 37 | 0.210 |
Why?
|
| Bacteriophages | 1 | 2024 | 45 | 0.210 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2006 | 184 | 0.200 |
Why?
|
| Clinical Competence | 1 | 2006 | 863 | 0.160 |
Why?
|
| Perception | 1 | 2021 | 187 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2021 | 100 | 0.150 |
Why?
|
| Patient Preference | 1 | 2021 | 136 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2021 | 413 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 872 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 660 | 0.120 |
Why?
|
| Decision Making | 1 | 2021 | 685 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1536 | 0.110 |
Why?
|
| Uterine Prolapse | 1 | 1994 | 82 | 0.100 |
Why?
|
| Vagina | 1 | 1994 | 186 | 0.090 |
Why?
|
| Female | 4 | 2024 | 51464 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 7386 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2021 | 9682 | 0.080 |
Why?
|
| Humans | 7 | 2024 | 97883 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1986 | 5 | 0.060 |
Why?
|
| Indomethacin | 1 | 1986 | 58 | 0.060 |
Why?
|
| Pelvis | 1 | 2006 | 106 | 0.060 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 1986 | 45 | 0.060 |
Why?
|
| Host Specificity | 1 | 2024 | 14 | 0.050 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2024 | 11 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 52 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2024 | 117 | 0.050 |
Why?
|
| Virulence | 1 | 2024 | 280 | 0.050 |
Why?
|
| Middle Aged | 2 | 2021 | 29353 | 0.050 |
Why?
|
| Aged | 1 | 2021 | 21702 | 0.050 |
Why?
|
| Learning | 1 | 2006 | 310 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 1994 | 2680 | 0.050 |
Why?
|
| Menorrhagia | 1 | 1994 | 28 | 0.030 |
Why?
|
| Herniorrhaphy | 1 | 1994 | 95 | 0.020 |
Why?
|
| Gynecology | 1 | 1994 | 135 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 12698 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 1986 | 18 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1986 | 80 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1986 | 62 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1986 | 48 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 28899 | 0.010 |
Why?
|
| Risk | 1 | 1986 | 660 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1986 | 2529 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1994 | 10947 | 0.010 |
Why?
|
| Prognosis | 1 | 1986 | 4112 | 0.010 |
Why?
|